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Background: An inositol 1,4,5-trisphosphate binding protein, comprising 2 isoforms termed PRIP-1 and PRIP-2, was
identified as a novel modulator for GABAA receptor trafficking. It has been reported that naive PRIP-1 knockout mice
have hyperalgesic responses.
Findings: To determine the involvement of PRIP in pain sensation, a hind paw withdrawal test was performed
before and after partial sciatic nerve ligation (PSNL) in PRIP-1 and PRIP-2 double knockout (DKO) mice. We found
that naive DKO mice exhibited normal pain sensitivity. However, DKO mice that underwent PSNL surgery showed
increased ipsilateral paw withdrawal threshold. To further investigate the inverse phenotype in PRIP-1 KO and DKO
mice, we produced mice with specific siRNA-mediated knockdown of PRIPs in the spinal cord. Consistent with the
phenotypes of KO mice, PRIP-1 knockdown mice showed allodynia, while PRIP double knockdown (DKD) mice with
PSNL showed decreased pain-related behavior. This indicates that reduced expression of both PRIPs in the spinal
cord induces resistance towards a painful sensation. GABAA receptor subunit expression pattern was similar
between PRIP-1 KO and DKO spinal cord, while expression of K+-Cl--cotransporter-2 (KCC2), which controls the
balance of neuronal excitation and inhibition, was significantly upregulated in DKO mice. Furthermore, in the DKD
PSNL model, an inhibitor-induced KCC2 inhibition exhibited an altered phenotype from painless to painful
sensations.
Conclusions: Suppressed expression of PRIPs induces an elevated expression of KCC2 in the spinal cord, resulting
in inhibition of nociception and amelioration of neuropathic pain in DKO mice.
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Background
We identified a D-myo-inositol 1,4,5-triphosphate-binding
protein with a domain organization similar to phospho-
lipase C-δ, but with no enzymatic activity. We therefore
termed this protein phospholipase C-related but catalyt-
ically inactive protein (PRIP) [1-3]. PRIP exists in 2 sub-
types and can bind to GABAA receptor β subunits [4],
GABAA receptor associated protein [5], and protein
phosphatase 1 and 2A [6,7].* Correspondence: tkanema2@hiroshima-u.ac.jp
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reproduction in any medium, provided the orNaive PRIP-1 knockout (KO) mice demonstrate a
marked decrease in the withdrawal threshold in the von
Frey hair test because of altered expression of GABAA
receptor subunit in their central nervous system [8]. In
the present study, we investigated the role of PRIP-1 and
PRIP-2 in pain sensation using PRIP-1 and PRIP-2 double
knockout (DKO) mice, and PRIP-1 and/or PRIP-2 knock-
down (KD) mice.Materials and methods
Animals
Ten- to fourteen-week-old male PRIP-1 KO [5,8] and
DKO [7,9] mice, in a C57BL/6J mouse background, and
ddY mice were used. All procedures and handling ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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the guidelines of Hiroshima University.
Seltzer model and paw withdrawal threshold test
Partial sciatic nerve ligation (PSNL) was performed ac-
cording to the procedure described by Seltzer et al. [10]. A
paw withdrawal threshold in response to probing with von
Frey hair (gram weight to buckling) was measured.
Generation of PRIP knockdown mice by intrathecal injection
with siRNA
Three siRNA target sequences for each PRIP-1 and PRIP-2
gene were designed using a manufacturer-provided soft-
ware (see Table 1). Synthetic siRNAs (0.45 pmol [0.15 pmol
for each]/5 μl/animal, purchased from iGENE, Therapeutics
Inc., Tokyo, Japan) were injected into the subarachnoid
space between L5 and L6 vertebrae of mice using
hemagglutinating virus of Japan envelope (HVJ-E) vector
system (GenomeONE; Ishihara Sangyo Kaisha, Ltd., Osaka,
Japan) [11].
Immunoblot analysis
The region of L5 and L6 vertebrae, into which siRNAs
were injected, was homogenized at 3 days postinjection
with a homogenization buffer, and whole-cell fractions
(for PRIPs, K+-Cl--cotransporter-2 [KCC2], Na+-K+-Cl--
cotransporter-1 [NKCC1], glycine receptor [GlyR] α1,
and tubulin) or cell membrane fractions (for GABAA re-
ceptor subunits) were obtained [12]. The homogenates
were subjected to SDS-PAGE followed by immunoblotting
using specific primary antibodies of interest. Antibodies
used are as follows: anti-PRIP-1 antibody [5], anti-PRIP-2
antibody [13], anti-β tubulin (Thermo Scientific, CA),
anti-GABAA receptor α1 subunit, anti-NKCC1 (Alpha
Diagnostic International, TX), anti-GABAA receptor α2
subunit (Aviva Systems Biology, CA), anti-GABAA
receptor α5 subunit (R&B Systems, MN), anti-GABAA
receptor α6 subunit (Imgenex, CA), anti-GABAA recep-
tor α4, β2/3, and γ2 subunit, anti-GlyRα1 (Merck
Millipore, MA), anti-KCC2 (Santa Cruz Biotechnology,
CA), and anti-phosphoserine (Acris antibodies, CA)
antibodies. An enhanced chemiluminescence western
detection system (Nacalai Tesque Inc., Kyoto, Japan)Table 1 The sequences used in siRNA knockdown
methods






#3: 5′-GCCGGAGCAGCAUCAUCAAGGAUGG-AG-3′was used for development (ImageQuant™ LAS 4000
mini detection system; GE Healthcare Japan).
Statistical analyses
The density of each band was analyzed using NIH ImageJ
software, and the densitometric units were corrected for
tubulin. The data were expressed as the mean ± S.E.M.
Statistical analyses are described in the figure legends.
Results and discussion
To examine pain-related behavior in DKO mice, PSNL
was performed, and the withdrawal threshold of the hind
paw was measured by applying von Frey filaments. Naive
DKO mice had normal sensation levels in terms of with-
drawal threshold (Figure 1A). This differed greatly from
the significant reduction in the withdrawal threshold ob-
served in PRIP-1 KO mice [8]. After PSNL, the withdrawal
threshold in the contralateral hind paw of DKO mice was
not significantly different from presurgical baselinesFigure 1 Pain-related behavior in WT and DKO mice. (A, B) Paw
withdrawal threshold in the von Frey hair test was measured 10
days after nerve injury by using naive mice (A) or neuropathic pain
model mice (B). The thresholds of PSNL-operated contralateral
(Contra) and ipsilateral (Ipsi) sides were assessed in (B). Column chart
shows withdrawal threshold in WT (open column) and DKO (closed
column) mice (mean ± S.E.M., n = 7–10). *P < 0.05 versus the
corresponding WT values (Student’s t-test). (C) Alteration of spinal
PRIP-1 and PRIP-2 expression 10 days after sham operation (open
column) or PSNL (close column) in naive C57BL/6 mice assessed by
immunoblotting. The levels of immunoreactivity were normalized to
that of β-tubulin and represented as % induction compared with
the values of WT mice (means ± S.E.M., n = 4).
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drawal threshold of wild-type (WT) ipsilateral hind paw
was dramatically ameliorated in the DKOmice (Figure 1B),
suggesting that DKO mice exhibit a neuropathic pain-
resistant phenotype. Since PRIP expression in WT mice
was similar to that in the PSNL and sham-operated mice
(Figure 1C), the onset of neuropathic pain was not induced
by the change of PRIP expression.
To better understand the involvement of PRIP in noci-
ceptive signaling, we produced the spinal cord-specific
PRIP-1 knockdown (PRIP-1 KD), PRIP-2 knockdown
(PRIP-2 KD), and PRIP-1 and PRIP-2 double knockdown
(DKD) mice by using molecular specific siRNAs (Table 1)
in the ddY mouse strain. We reported that a peak of gene
suppression following intrathecal injection of a siRNA
occurs at 2–3 days postinjection, and this recovers to
original levels approximately 8 days after injection
[14]. The significantly reduced expression of PRIP-1 in
PRIP-1 KD and DKD mice, or of PRIP-2 in PRIP-2 KD
and DKD mice, was observed 3 days after the siRNA
injection (Figure 2A and B). We then examined mechan-
ical allodynia by using the von Frey hair test in animals 3
days after siRNA injection. Allodynia was observed in the
PRIP-1 KD mice, but not in the other mice (Figure 2C),
indicating that the PRIP-1 KD mice mimicked the pheno-
types of pain sensitivity observed in PRIP-1 KO mice.
Next, we observed the influence of suppression of the
PRIP gene on pain sensation by using a PSNL model.
PSNL was performed on ddY mice 10 days before intra-
thecal siRNA injection, after which an allodynia score of
contralateral and ipsilateral sides was analyzed during
the 8 days after the injection of PRIP siRNA. In the
contralateral paw, PRIP-1 KD mice showed an allodynia in
accordance with PRIP-1 fluctuation 2–5 days after siRNA
injection (initial score, 1.17 ± 0.09 at day 0; peak score,
0.46 ± 0.117 at day 2; and recovered score, 1.22 ± 0.08 at
day 8) (Figure 2D). The PRIP-1 protein expression was an-
alyzed by immunoblotting (data not shown). The allodynia
observed in PRIP-1 KD mice was not seen in PRIP-2 KD,
DKD, and other control mice (Figure 2D). However, the
withdrawal threshold for the ipsilateral paw was dramatic-
ally increased in DKD mice (initial score, 0.104 ± 0.02 at
day 0 and peak score, 0.628 ± 0.068 at day 3), but not other
experimental mice, including PRIP-1 KD and PRIP-2 KD
mice; the relief gradually reverted to painful levels within
7 days (Figure 2E). This suggested that suppression of
both PRIP genes, but not either, induces resistance for
pain sensation associated with allodynia.
Neuropathic pain in a model animal induces an altered
expression of GABAA receptors, including the down-
regulation of γ2 subunit-containing receptors [15,16].
PRIP is a modulator for GABAA receptor intracellular
trafficking [7,9,17]. The β 2/3 subunit is upregulated, and
the γ2 subunit is downregulated in the spinal cord ofPRIP-1 KO or DKO mice [8,18]. Therefore, we exam-
ined the expression levels of GABAA receptor subunits
by immunoblotting using commercially available subunit-
specific antibodies. The examined expressions were similar
between the genotypes, with the exception of α5 expres-
sion, which was increased in DKO mice (Figure 3A).
Knabel et al. reported that α2 and α3 contribute to
diazepam-induced antihyperalgesia actions, but that α1
and α5 subunits do not [19], suggesting less involvement
of spinal α5 subunit-containing GABAA receptors in
nociception [16]. Therefore, the different pain sensation
between PRIP-1 KO and DKO mice is probably not due to
the alteration of GABAA receptor expression in the spinal
cord.
Inhibitory signaling is regulated by the intracellular
chloride ion concentration, which is established in part via
KCC2. Therefore, a high level of KCC2 expression drives
chloride extrusion from neurons and maintains a low
intracellular chloride ion concentration, i.e., GABAergic
input may even acquire a net cell inhibitory response [20].
We next examined KCC2 expression by immunoblotting.
The expression in PRIP-1 KO spinal cord was similar to
that in WT; however, the expression in DKO mice was
significantly increased compared with WT and PRIP-1 KO
mice (Figure 3B). We then investigated the influence of
PSNL surgery on expression of NKCC1 and KCC2,
both of which are required for maintaining a fine bal-
ance between chloride ion influx and efflux, respect-
ively (Figure 3C). KCC2 expression was higher in DKO
sham-operated mice than in corresponding WT mice.
PSNL surgery induced decreased KCC2 expressions in
WT and DKO mice compared with sham-operated
mice. Despite the decrease, KCC2 levels in DKO PSNL
mice were similar to those in WT sham-operated mice.
On the other hand, expression levels of NKCC1 were
similar, and PSNL surgery did not affect the expres-
sions (Figure 3C). We also examined expression of
GlyR, contributing as a chloride ion channel domin-
antly expressing in the spinal cord, whose activation is
known to ameliorates neuropathic pain [14]. Expres-
sions of GlyRα1, a most prevalent subunit in central
nervous system [21], were similar in the genotypes and
were not changed by PSNL operation (Figure 3C).
These data suggested that PRIP deficiency affects the
expression of KCC2 at basal and after PSNL surgery.
Since PRIP-2 KO mice are not currently available, we
were unable to define changes of GABAA receptor,
KCC2, NKCC2, and GlyRα1 expressions as a result of
PRIP-2 KO alone.
In immature neurons, a low expression of KCC2 re-
sults in a physiologically high concentration of intracel-
lular chloride ions, which leads to the depolarization of
cells [22]. Similarly, when PSNL was performed in mice,
KCC2 expression was decreased in the spinal cord,
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ide ion and reduced nociceptive threshold [23]. In
addition, upregulation of KCC2 induced inhibitory post-
synaptic potentials [24], suggesting that high expression
level of KCC2 observed with DKO spinal cord enhances
inhibitory synaptic transmission. We then tested if
inactivation of KCC2 by R-(+)-[(dihydroindenyl)oxy]
alkanoic acid (R-DIOA), an inhibitor of KCC2, affectsA B
C D
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Figure 2 Involvement of PRIPs in the pain-related behavior. (A, B) Exp
and DKD mice 3 days after intrathecal siRNA injection. Immunoblot analyse
HVJ-envelope (HVJ-E) or scrambled siRNA (SC) was used as a negative cont
level of immunoreactivity was normalized to β-tubulin and represented as
(means ± S.E.M., n = 4). *P < 0.05, †P < 0.05, ‡P < 0.05, §P < 0.05 and ¶P < 0.0
PRIP-1 KD, and PRIP-2 KD mice, respectively (Tukey-Kramer test). (C) Influenc
intrathecal siRNA injection in mice. Paw withdrawal threshold was measure
injection. Values represent withdrawal threshold (mean ± S.E.M., n = 5–10).
injection (Student’s t-test). (D, E) Influence on pain sensitivity by the suppre
threshold of both contralateral (D) and ipsilateral (E) sides were measured
the PSNL surgery represent as “naive.” Lines used in graphs are as follows:
HVJ-envelope, and scrambled siRNA-injected mice, respectively. Values repr
with the corresponding values of untreated mice (day 0) (Dunnet test).pain sensitivity. The paw withdrawal threshold was
decreased dose-dependently by intrathecal adminis-
tration of R-DIOA (Figure 3D), indicating the im-
portance of KCC2 activity. Therefore, similar KCC2
expression in the spinal cord of naive WT and DKO
PSNL mice (Figure 3C) may cause the allodynia-
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ression of PRIP-1 and PRIP-2 in the spinal cord of PRIP-1 KD, PRIP-2 KD
s were conducted using anti-PRIP-1 (A) and anti-PRIP-2 (B) antibodies.
rol. For each, a representative image is shown in the upper panel. The
% induction compared with the values of untreated mice (control)
5 compared with the corresponding values in untreated, SC, HVJ-E,
e on pain sensitivity by the suppression of the PRIP gene using
d the day before (open column) and 3 days after (closed column)
**P < 0.01 compared with the corresponding values from before
ssion of the PRIP gene in PSNL-operated mice. Paw withdrawal
each day after the intrathecal siRNA injection (day 0). The values before
green, violet, blue, black, and red are for PRIP-1 KD, PRIP-2 KD, DKD,
esent withdrawal threshold (mean ± S.E.M., n = 7). *P < 0.05 compared
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neuropathic pain regulated by PRIP, we performed a
hind paw withdrawal test by using WT, PRIP-1 and
PRIP-2 KD, and DKD mice with R-DIOA. Withdrawal
thresholds were not changed in PSNL-operated WT and a
single gene KD mice, and R-DIOA administration did not





































Figure 3 Alteration of expression of GABAA receptor subunits and KC
PRIP-1 KO (open column) and DKO (close column) mice. Expression levels o
as 100%, n = 5). *P < 0.05, for values in DKO vs PRIP-1 KO mice (Student’s t-t
(close column) mice. Expression levels represent each corresponding WT va
t-test). (C) Expression of GlyRα1 subunit, NKCC1 and KCC2 in WT and DKO
immunoreactivity was normalized to β-tubulin (mean ± S.E.M., n = 5–7). *P
(D) R-DIOA administration induces pain relation behavior. Intrathecal admin
withdrawal threshold in WT mice. (E) Influence of KCC2 activity on pain sen
after PSNL surgery. After 3 days of siRNA injection, R-DIOA (3 μg/mouse) w
out 30 min after the injection. PSNL-operated WT mice were also treated w
performed a paw withdrawal test. Naive represents prior to the surgery. Lin
WT, PRIP-1 KD, PRIP-2 KD, and DKD mice, respectively. The graph shows the
in 30 min after injection vs before injection (Student’s t-test).pain (as indicated by the increase of the threshold) in the
DKD PSNL model was significantly inhibited by the ad-
ministration of R-DIOA 3 days postinjection (Figure 3E).
Conclusions
We demonstrated that the regular expression of KCC2
















C2 in KO or KD mice. (A) Expression of GABAA receptor subunits in
f PRIP-1 KO and DKO are based on the corresponding WT (represented
est). (B) Expression of KCC2 in PRIP-1 KO (open column) and DKO
lue as 100%. *P < 0.05, for values in DKO vs PRIP-1 KO mice (Student’s
1 day after PSNL or sham operation (sham). The level of
< 0.05, compared with values in WT sham-operated mice (Dunnet test).
istration of R-DIOA dose-dependently induced a decreased pain
sitivity in PSNL mice. Each siRNA injection was performed 10 days
as administrated intrathecally, and a paw withdrawal test was carried
ith R-DIOA at 8 days after the surgery (representing as 8 in graph) and
es used in graph are as follows: black, green, violet, and blue are for
withdrawal threshold value (mean ± S.E.M., n = 8). *P < 0.05, for values
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PSNL-mediated neuropathic pain, even though the alter-
ation of GABAA receptor subunits in PRIP-1 KO mice
causes allodynia [8]. The current findings led us to
hypothesize that regulation of KCC2 expression is a critical
modulator of pain sensation.
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